Abstract: The present disclosure is directed to the use of a composition comprised of: (1) a first active blend of at least: (a) Jojoba oil/Macadamia seed oil esters; (b) squalene; (c) phytosteryl macadamiate; and (d) phytosterols; (2) a second active blend of at least: (e) EGF growth factor; (f) IGF-1 growth factor; (g) acidic FGF growth factor; (h) basic FGF growth factor; (i) VEGF growth factor; (j) vitamin B9; and (k) acetyl glutamine; and (3) a third active blend of at least: (l) an extract of lithothamnium calcareum; (m) pentylene glycol; (n) lactic acid; and (o) glycerin; (4) an emulsifier; and (5) a dermatologically acceptable carrier which, when applied onto skin, helps to positively influence inflammation, hydration, and keratinocyte hyperproliferation, thereby supporting skin barrier health, integrity, and functionality.

Abstract: Described herein in an embodiment is a lateral flow assay strip for detecting the presence of one or more target nucleic acid sequences (e.g., one or more nucleic acid sequences of a pathogen, such as a coronavirus or an influenza virus). The lateral flow assay strip may comprise a first test line configured to detect a first target nucleic acid sequence and a flow control line configured to detect a liquid. In some cases, the first test line comprises a biological capture reagent (e.g., an immobilized antibody). In some cases, the flow control line comprises a non-biological fluid indicator (i.e., a non-antibody reagent). The non-biological fluid indicator may, for example, comprise a pH-sensitive material, a moisture-sensitive material, and/or a chemically-sensitive material. The flow control line may provide a visual indication of whether a fluidic sample was successfully transported from a first end of the lateral flow assay strip to the first test line.

Abstract: Aspects of the disclosure relate to compositions and methods for amplifying and/or detecting one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens), and use of a trap region or reagent to reduce the level of one or more target nucleic acid analytes in an amplified sample prior to or in conjunction with detection. In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. In some embodiments, the methods comprise isothermal amplification of a target nucleic acid and subsequent reduction in the level of one or more target nucleic acid analytes and detection of the amplification products.